Guardant Health
About Guardant Health
Guardant Health provides blood-based cancer tests that enable early detection, guide targeted therapy selection for advanced disease, and monitor for minimal residual disease. Their platform analyzes circulating tumor DNA (ctDNA) using proprietary epigenomic and genomic profiling to improve clinical decision-making and patient outcomes.
<problem> Traditional cancer detection and treatment selection methods often involve invasive procedures and can be time-consuming, potentially delaying critical interventions. Furthermore, existing screening options for certain cancers face challenges with patient adherence due to inconvenience or discomfort. This can lead to delayed diagnoses and suboptimal treatment outcomes. </problem> <solution> Guardant Health offers a suite of advanced blood-based tests designed to provide comprehensive insights across the cancer care continuum. Leveraging liquid biopsy technology, their platform enables early cancer detection, aids in the selection of targeted therapies for advanced disease, and monitors for minimal residual disease (MRD) to predict recurrence. By analyzing circulating tumor DNA (ctDNA) and utilizing proprietary epigenomic and genomic profiling, Guardant Health aims to improve clinical decision-making and patient outcomes. Their approach seeks to overcome the limitations of traditional methods by offering less invasive, more accessible diagnostic tools. </solution> <features> - **Shield™ Blood Test:** A blood-based screening test for colorectal cancer that analyzes genomic alterations, methylation patterns, and fragmentomic signals to detect early signs of the disease in asymptomatic individuals. - **Guardant Complete® Portfolio:** A comprehensive genomic profiling solution for advanced cancer, enabling the identification of actionable biomarkers to guide targeted therapy selection. This includes tests that can assess HER2 mutation status and other key genomic alterations. - **Guardant Infinity™ Platform:** A proprietary, non-destructive DNA methylation technology that enhances molecule recovery for increased sensitivity in ctDNA detection. This platform supports multiomic insights, combining genomic, epigenomic, and RNA-based fusion data for applications such as MRD detection and molecular response monitoring. - **Guardant Reveal®:** A blood test designed for early-stage cancer patients to detect and quantify minimal residual disease (MRD) using methylation-based ctDNA analysis, aiding in the prediction of cancer recurrence and informing adjuvant therapy decisions. - **Guardant 360 Response™:** A test that monitors a patient's response to treatment, allowing for dynamic adjustments to therapy based on evolving molecular profiles. - **BioPharma Solutions:** Services tailored for pharmaceutical partners, providing genomic and epigenomic profiling for translational research and clinical trial support. - **AI-driven Data Analytics:** Utilization of real-world data and artificial intelligence to derive deeper insights from genomic and epigenomic analyses. </features> <target_audience> Guardant Health serves patients, healthcare providers (oncologists, pathologists, primary care physicians), and biopharmaceutical companies involved in cancer research and treatment. </target_audience> <revenue_model> Revenue is generated through the sale of diagnostic tests to healthcare providers and biopharmaceutical partners, with pricing structures varying based on the specific test and volume. </revenue_model>
What does Guardant Health do?
Guardant Health provides blood-based cancer tests that enable early detection, guide targeted therapy selection for advanced disease, and monitor for minimal residual disease. Their platform analyzes circulating tumor DNA (ctDNA) using proprietary epigenomic and genomic profiling to improve clinical decision-making and patient outcomes.
Where is Guardant Health located?
Guardant Health is based in Palo Alto, United States.
- Location
- Palo Alto, United States
- Employees
- 3719 employees